Xihong Biopharma recently participated in IMCAS Americas 2026 held in São Paulo, one of the most influential medical aesthetics congresses in Latin America. The event brought together dermatologists, plastic surgeons, aesthetic clinics, and distributors from across the region, providing an important platform for industry exchange, innovation showcase, and international collaboration.
At the exhibition, Xihong Biopharma presented its portfolio of regenerative aesthetic biomaterials, including PLLA-based fillers, CaHA biostimulators, and advanced dermal filler technologies designed to stimulate collagen production and deliver natural-looking, long-lasting aesthetic outcomes.
Among the technologies showcased, PLLA Body Fillers and CaHA-based biostimulators attracted significant attention from aesthetic professionals visiting the booth.
As the global aesthetic industry increasingly shifts toward collagen-stimulating injectables and regenerative treatments, these technologies have become key solutions for both facial rejuvenation and body contouring. Visitors expressed strong interest in the use of PLLA for body contouring and skin quality improvement, as well as CaHA technologies for facial structural support and collagen stimulation.
The strong engagement during the event reflects the growing demand across Latin America for advanced biomaterial-based aesthetic solutions that combine safety, durability, and natural aesthetic results.
As part of its long-term international development strategy, Xihong Biopharma has completed key documentation related to Brazilian GMP and ANVISA requirements, marking an important milestone in the company’s regulatory preparations.
With this regulatory groundwork in place, Xihong Biopharma is accelerating its strategic expansion into Brazil, reinforcing its commitment to global quality standards and sustainable development within the Latin American aesthetic market.
Participation in IMCAS Americas 2026 also enabled the company to deepen engagement with distributors, clinics, and industry partners from Brazil and neighboring markets. Many visitors expressed interest in Xihong Biopharma’s private label and ODM collaboration models, as well as its expertise in biomaterial-based aesthetic technologies.
As demand for PLLA body fillers and CaHA biostimulators continues to grow globally, Xihong Biopharma remains committed to expanding partnerships with distributors and aesthetic professionals seeking reliable, high-quality collagen-stimulating injectable solutions.
Xihong Biopharma will continue to connect with partners and industry professionals at upcoming international exhibitions:
Beauty Istanbul| May 7–9
Dubai Derma | June 30 – July 2
Visitors interested in PLLA body fillers, CaHA biostimulators, or private label collaboration are welcome to connect with our team during the exhibitions.
